Narrative review examines efflux-mediated fluoroquinolone resistance in gram-negative bacteria, highlighting rising therapeutic challenges across diverse infections.
The introduction of the fluoroquinolones (FQs) in the 1980s provided clinicians with a class of broad-spectrum agents applicable to a range of gram-negative infections including urinary tract infections, gastrointestinal infections, respiratory tract infections, sexually transmitted diseases, bone
No takes yet. Share an insight, caveat, or question.
Keith Poole (2000) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: